Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $16.62 and traded as high as $17.00. Theravance Biopharma shares last traded at $16.97, with a volume of 317,513 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TBPH shares. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. B. Riley Financial upped their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat, Theravance Biopharma currently has an average rating of “Hold” and a consensus target price of $19.40.

Theravance Biopharma Trading Up 0.2%

The company has a market cap of $874.80 million, a P/E ratio of 7.71 and a beta of 0.17. The company has a 50 day moving average price of $16.62 and a 200-day moving average price of $17.18.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. Equities analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Insider Activity

In other news, major shareholder Eli Samaha sold 273,871 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the sale, the insider directly owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 350,011 shares of company stock valued at $6,008,309. Insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors have recently added to or reduced their stakes in TBPH. Mirae Asset Global Investments Co. Ltd. boosted its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares in the last quarter. Creative Planning increased its holdings in shares of Theravance Biopharma by 6.7% during the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 842 shares in the last quarter. State of Wyoming lifted its stake in shares of Theravance Biopharma by 5.7% in the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 1,019 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 1,020 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.